Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28- Antitumor T Cells

Cancer Research

Volumn 64, Issue 6, 2004, Pages 2175-2182

  Conejo Garcia, Jose R ^a   Benencia, Fabian ^a   Courreges, Maria C ^a   Gimoty, Phyllis A ^a   Khang, Eugene ^a   Buckanovich, Ronald J ^a   Frauwirth, Kenneth A ^a   Zhang, Lin ^a   Katsaros, Dionyssios ^b   Thompson, Craig B ^a   Levine, Bruce ^a   Coukos, George ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD8 ANTIGEN; GLUCOSE TRANSPORTER 1; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN LETHAL; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL PROTECTION; CONTROLLED STUDY; FEMALE; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; OVARY CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADENOCARCINOMA, MUCINOUS; ANIMALS; ANTIGENS, CD28; APOPTOSIS; CARCINOMA, ENDOMETRIOID; CD8-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; CYSTADENOCARCINOMA, SEROUS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; LIGANDS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 12144289172     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2194     Document Type: Article

References (31)

1. Yee C, Greenberg P. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer 2002;2:409-19.
2. Pardoll DM. Immunology. Stress, NK receptors, and immune surveillance. Science (Wash. DC) 2001;294:534-6.
3. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
4. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
5. Rivoltini L, Carrabba M, Huber V, et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash. DC) 2002;298:850-4.
7. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T-cell receptor in tumor-associated lymphocytes. J Clin Investig 1998;101:2579-88.
8. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science (Wash. DC) 1999;285:727-9.
9. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-60.
10. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (Lond.) 2001;413:165-71.
11. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
12. Girardi M, Oppenheim DE, Steele CR, et al. Regulation of cutaneous malignancy by γδ T cells. Science (Wash. DC) 2001;294:605-9.
13. Conejo-Garcia JR, Benencia F, Courreges MC, et al. LETAL, a tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther 2003;2:446-51.
14. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-8.
15. Garcia JR, Krause A, Schulz S, et al. Human β-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J 2001;15:1819-21.
16. Frauwirth KA, Riley JL, Harris MH, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002;16:769-77.
17. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996;174:116-28.
18. Azuma M, Phillips JH, Lanier LL. CD28-T lymphocytes. Antigenic and functional properties. J Immunol 1993;150:1147-59.
19. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
20. Plas DR, Rathmell JC, Thompson CB. Homeostatic control of lymphocyte survival: potential origins and implications. Nat Immunol 2002;3:515-21.
21. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 1999;162:3273-9.
22. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001;98:11521-6.
23. Levine AD, Fiocchi C. Regulation of life and death in lamina propria T cells. Semin Immunol 2001;13:195-9.
24. Westermann J, Engelhardt B, Hoffmann JC. Migration of T cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 2001;135:279-95.
25. Kataoka T, Budd RC, Holler N, et al. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr Biol 2000;10:640-8.
26. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel AE. The NF-κB cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000;165:1743-54.
27. Kirchhoff S, Muller WW, Li-Weber M, Krammer PH. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur J Immunol 2000;30:2765-74.
28. Vander Heiden MG, Chandel NS, Schumacker PT, Thompson CB. Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. Mol Cell 1999;3:159-67.
29. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature (Lond.) 2002;419:734-8.
30. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-33.
31. Boon T, van Baren N. Immunosurveillance against cancer and immunotherapy: synergy or antagonism? N Engl J Med 2003;348:252-4.